Abstract：
Historically, neonatal neuroscience boasted a robust and successful preclinical pipeline for therapeutic interventions, in particular for the treatment of hypoxic-ischemic encephalopathy (HIE). However, since the successful translation of therapeutic hypothermia (TH), several high-profile failures of promising adjunctive therapies, in addition to the lack of benefit of TH in lower resource settings, have brought to light critical issues in that same pipeline. Using recent data from clinical trials of erythropoietin as an example, the authors highlight several key challenges facing preclinical neonatal neuroscience for HIE therapeutic development and propose key areas where model development and collaboration across the field in general can ensure ongoing success in treatment development for HIE worldwide.
摘要：
历史上,新生儿神经科学为治疗干预提供了强大而成功的临床前管道，特别是用于治疗缺氧缺血性脑病(HIE)。然而,由于治疗性低温(TH)的成功翻译，有希望的辅助疗法的几个引人注目的失败，除了TH在较低资源环境中缺乏优势之外，揭示了同一管道中的关键问题。以促红细胞生成素临床试验的最新数据为例，作者强调了临床前新生儿神经科学在HIE治疗开发方面面临的几个关键挑战,并提出了关键领域,在这些领域中,模型开发和整个领域的合作可以确保全球HIE治疗开发持续成功.
